Association between prostate-specific antigen change over time and prostate cancer recurrence risk: A joint model.
Joint modeling
Prostate cancer recurrence
Prostate specific antigen (PSA)
Journal
Caspian journal of internal medicine
ISSN: 2008-6164
Titre abrégé: Caspian J Intern Med
Pays: Iran
ID NLM: 101523876
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
ppublish
Résumé
Prostate specific antigen (PSA) is an important biomarker to monitor patients after treated with radiation therapy (RT). The aim of this study is to evaluate the relationship between the PSA data and prostate cancer recurrence using the joint modeling. This historical cohort study was performed on 422 prostate cancer patients. Inclusion criteria included: patients with localized prostate cancer referring to Cancer Institute in Tehran (Iran) from 2007 to 2012, and under radiation therapy. Joint model has two components or sub-models. We showed the results by parameter estimating the longitudinal sub-model and survival sub-model. EM algorithm, Newton-Gauss and Gauss-Hermit law were used for final model parameters. R software version 3.2 was used for statistical analysis. In this study, considering the inclusion and exclusion criteria, out of 422 patients, the data on 314 cases were selected for analysis and the main result of joint model was obtained. PSA directly and significantly was associated with recurrence risk, therefore increasing 2.6 ml/lit PSA (one unit in transformed PSA) increases 39% recurrence risk (95% CI for RR: 1.09-1.77). Also, slope of PSA trend has significant association with prostate cancer recurrence risk (95% CI for RR: 1.05-1.41). This study showed a significant relationship between PSA, and its slope with the recurrence risk by joint model, with regard to the pathological, demographic and clinical features in the Iranian population.
Sections du résumé
BACKGROUND
BACKGROUND
Prostate specific antigen (PSA) is an important biomarker to monitor patients after treated with radiation therapy (RT). The aim of this study is to evaluate the relationship between the PSA data and prostate cancer recurrence using the joint modeling.
METHODS
METHODS
This historical cohort study was performed on 422 prostate cancer patients. Inclusion criteria included: patients with localized prostate cancer referring to Cancer Institute in Tehran (Iran) from 2007 to 2012, and under radiation therapy. Joint model has two components or sub-models. We showed the results by parameter estimating the longitudinal sub-model and survival sub-model. EM algorithm, Newton-Gauss and Gauss-Hermit law were used for final model parameters. R software version 3.2 was used for statistical analysis.
RESULTS
RESULTS
In this study, considering the inclusion and exclusion criteria, out of 422 patients, the data on 314 cases were selected for analysis and the main result of joint model was obtained. PSA directly and significantly was associated with recurrence risk, therefore increasing 2.6 ml/lit PSA (one unit in transformed PSA) increases 39% recurrence risk (95% CI for RR: 1.09-1.77). Also, slope of PSA trend has significant association with prostate cancer recurrence risk (95% CI for RR: 1.05-1.41).
CONCLUSION
CONCLUSIONS
This study showed a significant relationship between PSA, and its slope with the recurrence risk by joint model, with regard to the pathological, demographic and clinical features in the Iranian population.
Identifiants
pubmed: 32874441
doi: 10.22088/cjim.11.3.324
pmc: PMC7442453
doi:
Types de publication
Journal Article
Langues
eng
Pagination
324-328Références
Stat Med. 2002 Dec 30;21(24):3897-911
pubmed: 12483774
Biostatistics. 2002 Dec;3(4):547-63
pubmed: 12933597
Asian Pac J Cancer Prev. 2015;16(7):2601-11
pubmed: 25854335
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Radiat Oncol. 2013 Jul 08;8:170
pubmed: 23835115
JAMA. 2005 Jul 6;294(1):66-70
pubmed: 15998892
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):941-7
pubmed: 9276358
Biostatistics. 2009 Jul;10(3):535-49
pubmed: 19369642
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):782-91
pubmed: 19014779
Biometrics. 2013 Mar;69(1):206-13
pubmed: 23379600
Asian Pac J Cancer Prev. 2012;13(11):5529-33
pubmed: 23317212
J Clin Oncol. 2005 Feb 1;23(4):816-25
pubmed: 15681526
Radiat Oncol. 2014 Feb 02;9:42
pubmed: 24484652